BBHC
ACRS icon

Brown Brothers Harriman & Co’s Aclaris Therapeutics ACRS Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,588
Closed -$45 – 1150
2021
Q2 		$45 Buy
+2,588
New +$58.8K ﹤0.01% 687
2017
Q1 		– Sell
-3,195
Closed -$87K – 791
2016
Q4 		$87K Buy
+3,195
New +$81.5K ﹤0.01% 413

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Brown Brothers Harriman & Co's ACRS Position: Q3 2021 in Review

Brown Brothers Harriman & Co sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 2,588 shares — an estimated $45 sold.

Brown Brothers Harriman & Co first reported a position in ACRS in Q4 2016 and held it in 2 quarters. The position peaked at $87K in Q4 2016. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

  • Brown Brothers Harriman & Co reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 2,588 Aclaris Therapeutics shares in Q3 2021, an estimated $45.
  • Brown Brothers Harriman & Co first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 2 quarters.
  • Brown Brothers Harriman & Co's Aclaris Therapeutics position peaked at $87K in Q4 2016.
  • 126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.